Assembly Biosciences ASMB

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$0.16 (-1.40%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Assembly Biosciences (ASMB)
    Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $11.12

    • Market Cap

      $70.68 Million

    • Price-Earnings Ratio

      -1.61

    • Total Outstanding Shares

      6.36 Million Shares

    • Total Employees

      65

    • Dividend

      No dividend

    • IPO Date

      December 17, 2010

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      NASDAQ

    • Type

      Common Stock

    • Headquarters

      Two tower place, South san francisco, CA, 94080

    • Homepage

      https://www.assemblybio.com

    Historical Stock Splits

    If you bought 12 shares of ASMB before February 12, 2024, you'd have 1 share today.
    Execution DateSplit Amount
    February 12, 20241-for-12 (Reverse Split)

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Operating Activities, Continuing$22.94 Million
    Net Cash Flow From Investing Activities, Continuing$-42.79 Million
    Net Cash Flow$1.80 Million
    Net Cash Flow From Investing Activities$-42.79 Million
    Net Cash Flow From Operating Activities$22.94 Million
    Net Cash Flow From Financing Activities, Continuing$21.65 Million

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Basic Earnings Per Share$-6.92
    Income Tax Expense/Benefit$439,000
    Diluted Average Shares$12.16 Million
    Basic Average Shares$12.16 Million
    Diluted Earnings Per Share$-6.92
    Preferred Stock Dividends And Other Adjustments$0

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss Attributable To Parent$-40.69 Million
    Comprehensive Income/Loss$-40.69 Million
    Other Comprehensive Income/Loss$-9.49 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Other Non-current Assets$1.73 Million
    Fixed Assets$316,000
    Current Assets$98.21 Million
    Equity$26.00 Million
    Noncurrent Assets$2.05 Million
    Current Liabilities$41.63 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ASMB from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.